The impact of socioeconomic status on access to cancer clinical trials von Sharrocks, K, Spicer, J, Camidge, D R, Papa, S

Volltext

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers von Atherly, A J, Camidge, D R

Volltext

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced... von Doebele, R.C., Conkling, P., Traynor, A.M., Otterson, G.A., Zhao, Y., Wind, S., Stopfer, P., Kaiser, R., Camidge, D.R.

Volltext

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 von Shaw, A.T., Riely, G.J., Bang, Y.-J., Kim, D.-W., Camidge, D.R., Solomon, B.J., Varella-Garcia, M., Iafrate, A.J., Shapiro, G.I., Usari, T., Wang, S.C., Wilner, K.D., Clark, J.W., Ou, S.-H.I.

Volltext

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study von Mok, T., Camidge, D.R., Gadgeel, S.M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Pérol, M., Ou, S.-H.I., Ahn, J.S., Shaw, A.T., Bordogna, W., Smoljanović, V., Hilton, M., Ruf, T., Noé, J., Peters, S.

Volltext

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study von Gadgeel, S., Peters, S., Mok, T., Shaw, A.T., Kim, D.W., Ou, S.I., Pérol, M., Wrona, A., Novello, S., Rosell, R., Zeaiter, A., Liu, T., Nüesch, E., Balas, B., Camidge, D.R.

Volltext

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry von Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.

Volltext

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma von Krug, A.K., Enderle, D., Karlovich, C., Priewasser, T., Bentink, S., Spiel, A., Brinkmann, K., Emenegger, J., Grimm, D.G., Castellanos-Rizaldos, E., Goldman, J.W., Sequist, L.V., Soria, J.-C., Camidge, D.R., Gadgeel, S.M., Wakelee, H.A., Raponi, M., Noerholm, M., Skog, J.

Volltext

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib von Wang, Y., Jiang, T., Qin, Z., Jiang, J., Wang, Q., Yang, S., Rivard, C., Gao, G., Ng, T.L., Tu, M.M., Yu, H., Ji, H., Zhou, C., Ren, S., Zhang, J., Bunn, P., Doebele, R.C., Camidge, D.R., Hirsch, F.R.

Volltext

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs von Felip, E., Shaw, A.T., Bearz, A., Camidge, D.R., Solomon, B.J., Bauman, J.R., Bauer, T.M., Peters, S., Toffalorio, F., Abbattista, A., Thurm, H., Peltz, G., Wiltshire, R., Besse, B.

Volltext

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumo... von Kris, M.G., Camidge, D.R., Giaccone, G., Hida, T., Li, B.T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M.E., Goldberg, Z., Jänne, P.A.

Volltext

A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer von Besse, B., Heist, R.S., Papadmitrakopoulou, V.A., Camidge, D.R., Beck, J.T., Schmid, P., Mulatero, C., Miller, N., Dimitrijevic, S., Urva, S., Pylvaenaeinen, I., Petrovic, K., Johnson, B.E.

Volltext

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer von Dasari, A., Gore, L., Messersmith, W. A., Diab, S., Jimeno, A., Weekes, C. D., Lewis, K. D., Drabkin, H. A., Flaig, T. W., Camidge, D. R.

Volltext

The epidemiology of self‐poisoning in the UK von Camidge, D. R., Wood, R. J., Bateman, D. N.

Volltext

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC von Peters, T. L., Patil, T., Le, A. T., Davies, K. D., Brzeskiewicz, P. M., Nijmeh, H., Bao, L., Camidge, D. R., Aisner, D. L., Doebele, R. C.

Volltext

Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA... von Garcia Campelo, M.R., Wan, Y., Lin, H.M., Chen, T., Shen, J., Zhang, P., Camidge, D.R.

Volltext

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer von Cameron, D A, Camidge, D R, Oyee, J, Hirsch, M

Volltext

Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data von Camidge, D R, Stockton, D L, Bain, M

Volltext

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma von Krug, A.K., Enderle, D., Karlovich, C., Priewasser, T., Bentink, S., Spiel, A., Brinkmann, K., Emenegger, J., Grimm, D.G., Castellanos-Rizaldos, E., Goldman, J.W., Sequist, L.V., Soria, J -C, Camidge, D.R., Gadgeel, S.M., Wakelee, H.A., Raponi, M., Noerholm, M., Skog, J.

Volltext

Hospital admissions and deaths relating to deliberate self-harm and accidents within 5 years of a cancer diagnosis: a national study in Scotland, UK von Camidge, D R, Stockton, D L, Frame, S, Wood, R, Bain, M, Bateman, D N

Volltext